Document is current
Any future updates will be listed below
-
Authors
McAllister, Peter
Cohen, Joshua M.
Campos, Verena Ramirez
Ning, Xiaoping
Janka, Lindsay
Barash, Steve
-
Funding
Funding for this research was provided by:
Teva Pharmaceuticals
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 10 June 2022
First Online: 29 August 2022
Declarations
:
: The study protocols used for the trials included in this analysis were approved by relevant ethics committees and institutional review boards. Additionally, these trials were conducted in accordance with the International Conference for Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, and relevant national and local regulations. Each patient provided written informed consent before any study procedures or assessments were performed.
: Not applicable.
: P. McAllister has received research support from and serves as a consultant for Alder Pharmaceuticals, Amgen, Eli Lilly, Novartis, and Teva Pharmaceuticals. J.M. Cohen is a former employee of Teva Pharmaceuticals. V Ramirez Campos, X. Ning, L. Janka, and S. Barash are employees of Teva Pharmaceuticals.
